Nivalis Therapeutics Inc. (NVLS) Lowered to Sell at Zacks Investment Research
Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. “
A number of other equities analysts have also recently weighed in on NVLS. Cowen and Company reissued a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st. HC Wainwright restated a “buy” rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th. Piper Jaffray Cos. restated a “buy” rating and set a $16.00 price objective on shares of Nivalis Therapeutics in a research report on Tuesday, August 30th. Finally, Raymond James Financial Inc. started coverage on Nivalis Therapeutics in a research report on Tuesday, September 13th. They set an “outperform” rating and a $20.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Nivalis Therapeutics currently has an average rating of “Buy” and a consensus price target of $13.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/nivalis-therapeutics-inc-nvls-lowered-to-sell-at-zacks-investment-research.html
Shares of Nivalis Therapeutics (NASDAQ:NVLS) opened at 7.38 on Wednesday. Nivalis Therapeutics has a 12 month low of $3.68 and a 12 month high of $9.45. The firm’s market cap is $114.41 million. The firm has a 50-day moving average of $7.48 and a 200 day moving average of $5.34.
Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings results on Monday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.03. On average, equities research analysts anticipate that Nivalis Therapeutics will post ($2.29) EPS for the current fiscal year.
In other news, EVP David Malcom Rodman sold 5,820 shares of Nivalis Therapeutics stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total transaction of $46,327.20. Following the completion of the sale, the executive vice president now directly owns 18,056 shares in the company, valued at approximately $143,725.76. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 3.00% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. BVF Inc. IL raised its stake in shares of Nivalis Therapeutics by 29.4% in the first quarter. BVF Inc. IL now owns 1,546,743 shares of the company’s stock valued at $6,450,000 after buying an additional 351,730 shares in the last quarter. State Street Corp raised its stake in shares of Nivalis Therapeutics by 4.5% in the first quarter. State Street Corp now owns 44,495 shares of the company’s stock valued at $186,000 after buying an additional 1,900 shares in the last quarter. Opaleye Management Inc. purchased a new stake in shares of Nivalis Therapeutics during the first quarter valued at about $417,000. Sabby Management LLC raised its stake in shares of Nivalis Therapeutics by 31.5% in the first quarter. Sabby Management LLC now owns 662,058 shares of the company’s stock valued at $2,761,000 after buying an additional 158,463 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of Nivalis Therapeutics during the second quarter valued at about $105,000. Institutional investors and hedge funds own 83.12% of the company’s stock.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.